Oribiotech’s US$120 million deal just answered one of cell therapy’s biggest commercial questions
Oribiotech, AdAlta’s cell therapy manufacturing automation partner, has signed a 10-year agreement worth up to US$120 million with an undisclosed commercial-stage biopharmaceutical company to integrate its IRO® platform into the manufacture of an already approved and commercialised cell therapy. For AdAlta Limited (ASX:1AD), the significance is direct: AdAlta, Ori, and Cell Therapies Pty Ltd (CTPL) already signed a Memorandum of Understanding in April 2026 to deploy IRO® in Australia and the Asia Pacific for AdAlta’s own cellular immunotherapy pipeline, meaning the platform AdAlta has chosen has now been independently validated by a commercial-stage manufacturer operating a product already on the market.
When big ASX news breaks, our subscribers know first
Why a commercial manufacturer moving an approved product onto IRO® is the highest possible endorsement
Cell therapy manufacturing is unlike any other pharmaceutical process. Each dose is made individually from a patient’s own living cells, making the manufacturing process effectively part of the product itself.
Companies change manufacturing processes for approved cell therapies reluctantly, and almost never once a product has reached market. Any change requires a company to demonstrate “comparability” to regulators — evidence that therapy produced under the new process performs identically to therapy produced under the old one. That work demands significant time, capital, and carries genuine regulatory risk.
The fact that a biopharmaceutical company with an already-approved, commercially marketed cell therapy has decided the advantages of IRO® outweigh that burden, and committed to a decade-long relationship worth up to US$120 million to pursue it, signals a level of conviction that no pilot programme or early-stage trial could replicate. This is, by definition, the highest bar in the industry.
Dr Tim Oldham, CEO and Managing Director, AdAlta Limited
“Congratulations to Jason Foster and the whole Oribiotech team. Winning a ten-year commitment of this size for an approved, marketed cell therapy is a remarkable achievement, and it says something important for AdAlta shareholders. When we chose to deploy IRO® we were backing a view that automation is what separates a cell therapy that merely works from a cell therapy that can be sold. A commercial manufacturer has now looked at the same platform and decided to move an already-approved product onto it. Nobody takes that decision lightly – it is the highest bar in our industry. It means the cellular immunotherapies we develop on IRO® will be made on a platform that our eventual partners have already validated, endorsed and put into commercial use. That takes a significant question off the table in any future partnering conversation.”
What IRO® actually does — and why manufacturing is make-or-break for cell therapy
Cell therapy manufacturing presents challenges that conventional pharmaceutical manufacturing does not. Because every dose is produced individually from a specific patient’s living cells, and because small changes in equipment or conditions can affect the therapy’s safety and efficacy, the manufacturing process carries a weight that is unique to this class of treatments.
IRO® is a fully closed, automated system designed to carry a cell therapy process from research through to commercial manufacture on a single platform. When AdAlta, Ori, and CTPL announced their Memorandum of Understanding in April 2026, four core capabilities were identified:
The IRO® manufacturing partnership announced in April 2026 established the three-party framework between AdAlta, Oribiotech, and CTPL, with IRO® carrying US FDA Advanced Manufacturing Technology designation and over 900 characterisation runs completed across 80 or more donor and patient samples at that point.
| Benefit | What It Means for Investors |
|---|---|
| Cost | Potential manufacturing cost reductions of 30–50%, addressing a primary reason these therapies remain inaccessible to most patients |
| Capacity | 10–50x more patient doses from the same physical footprint, without building additional clean rooms |
| Consistency | Automation and digitalisation of manual steps reduces batch-to-batch variation and the risk of a failed dose |
| Transferability | A process developed on IRO® scales to commercial manufacture without being rebuilt, and transfers between sites more readily |
Cost, capacity, consistency, and transferability are precisely the questions a pharmaceutical partner asks when evaluating a potential product acquisition or licensing deal. A product developed on IRO® arrives at those conversations with answers the industry has already validated at the commercial stage.
What this means for AdAlta’s pipeline and partnering strategy
One important distinction warrants clarity for shareholders. EW-001, AdAlta’s lead CAR-T cell therapy targeting mesothelioma, was selected in part because it already carried a robust, low-cost, and scalable manufacturing solution. That process is being transferred from Shanghai Cell Therapy Group Co Ltd (SHcell) to CTPL and will not be manufactured on IRO®. The IRO® collaboration does not alter EW-001’s manufacturing pathway.
The strategic shift applies to what comes next. IRO® compatibility is now a design priority for AdAlta’s future products, with the company prioritising “East to West” candidates whose manufacturing can be built on IRO® from the outset. This approach means future pipeline products would avoid the comparability burden that Ori’s new commercial partner has taken on, arriving at partnering conversations on a platform that large pharmaceutical companies have already validated and deployed.
The logic for shareholders is straightforward. AdAlta’s value is realised through partnerships with, or sales to, larger pharmaceutical companies, and manufacturing is one of the areas those companies scrutinise most closely. A product built on IRO® from day one sidesteps the regulatory and financial risk of a mid-stream process change.
AdAlta’s East to West commercialisation model targets an all-in investment of approximately US$15 million per asset against a median comparable deal value of US$782 million, a unit economics framework that CEO Dr Tim Oldham presented directly to pharmaceutical executives at the CAR-TCR Summit in Boston in September 2026.
The three forward-looking investor takeaways from the announcement are:
- EW-001 progresses on its existing manufacturing pathway, with the SHcell-to-CTPL transfer continuing as planned
- Future pipeline products will be designed for IRO® compatibility from the outset
- IRO® deployment at CTPL under the April 2026 Memorandum of Understanding will commence once active discussions to licence a suitable next product are concluded
AdAlta at a glance
AdAlta (ASX:1AD) is a clinical-stage biotechnology company focused on cellular immunotherapies for solid cancers. Its “East to West” strategy in-licenses products from Asian originators and advances them through US FDA-regulated manufacturing and Phase I clinical studies, with the aim of positioning each product for on-licensing to larger biopharmaceutical companies.
The company’s current pipeline includes:
- EW-001: CAR-T cell therapy for mesothelioma; lead asset; manufacturing transfer from SHcell to CTPL underway
- Future pipeline: IRO®-compatible products in active sourcing
- AD-214: First-in-class fusion protein for fibrotic diseases, including Idiopathic Pulmonary Fibrosis; available for partnering
- WD-34: Novel pan-strain malaria inhibitor; seeking grant funding
The cellular immunotherapy market is projected to grow at a compound annual growth rate (CAGR) of 34% to reach US$20.3 billion by 2028, a backdrop that underpins AdAlta’s focus on this segment.
Get ASX Healthcare News Before the Market Moves
Breaking ASX healthcare announcements land in your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ investors who rely on Big News Blast for FREE real-time coverage of the sector moves that matter. Click the “Free Alerts” button to start receiving alerts the moment market-moving healthcare news breaks.